**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the current application.

1. (Previously Presented) An ApoA-I agonist compound comprising:

(i) a 22 to 29-residue D-enantiomeric peptide or peptide analogue which forms an amphipathic α-helix in the presence of lipids and which comprises formula (I):

$Z_1$-$X_1$-$X_2$-$X_3$-$X_4$-$X_5$-$X_6$-$X_7$-$X_8$-$X_9$-$X_{10}$-$X_{11}$-$X_{12}$-$X_{13}$-$X_{14}$-$X_{15}$-$X_{16}$-$X_{17}$-$X_{18}$-$X_{19}$-$X_{20}$-$X_{21}$-$X_{22}$-$X_{23}$-$Z_2$

or a pharmaceutically acceptable salt thereof, wherein:

$X_1$ is D-Ala (a), Gly (G), D-Gln (q), D-Asn (n), D-Asp (d) or D-Pro (p);

$X_2$ is a D-enantiomeric aliphatic residue;

$X_3$ is D-Leu (l) or D-Phe (f);

$X_4$ is a D-enantiomeric acidic residue;

$X_5$ is D-Leu (l) or D-Phe (f);

$X_6$ is D-Leu (l) or D-Phe (f);

$X_7$ is a D-enantiomeric hydrophilic residue;

$X_8$ is a D-enantiomeric acidic or a basic residue;

$X_9$ is D-Leu (l) or Gly (G);

$X_{10}$ is D-Leu (l), D-Trp (w) or Gly (G);

$X_{11}$ is a D-enantiomeric hydrophilic residue;

$X_{12}$ is a D-enantiomeric hydrophilic residue;

$X_{13}$ is Gly (G) or a D-enantiomeric aliphatic residue;

$X_{14}$ is D-Leu (l), D-Trp (w), Gly (G) or D-Nal;

$X_{15}$ is a D-enantiomeric hydrophilic residue;

$X_{16}$ is a D-enantiomeric hydrophobic residue;

$X_{17}$ is a D-enantiomeric hydrophobic residue;

$X_{18}$ is D-Gln (q), D-Asn (n) or a D-enantiomeric basic residue;

$X_{19}$ is D-Gln (q), D-Asn (n) or a D-enantiomeric basic residue;

$X_{20}$ is a D-enantiomeric basic residue;

$X_{21}$ is a D-enantiomeric aliphatic residue;

$X_{22}$ is a D-enantiomeric basic residue;

$X_{23}$ is absent or a D-enantiomeric basic residue;

$Z_1$ is $R_2N$- or RC(O)NR-;

$Z_2$ is -C(O)NRR, -C(O)OR or -C(O)OH or a salt thereof;

each R is independently -H, ($C_1$-$C_6$) alkyl, ($C_1$-$C_6$) alkenyl, ($C_1$-$C_6$) alkynyl, ($C_5$-$C_{20}$) aryl, ($C_6$-$C_{26}$) alkaryl, 5-20 membered heteroaryl, 6-26 membered alkheteroaryl or a 1 to 7-residue peptide or peptide analogue in which one or more bonds between residues 1 through 7 are independently a substituted amide, an isostere of an amide or an amide mimetic; and

each " - " between residues $X_1$ through $X_{23}$ independently designates an amide linkage, a substituted amide linkage, an isostere of an amide or an amide mimetic; or

(ii) a 22 to 29-residue altered D-enantiomeric peptide or peptide analogue according to formula (I) in which at least one of residues $X_1$, $X_2$, $X_3$, $X_4$, $X_5$, $X_6$, $X_7$, $X_8$, $X_9$, $X_{10}$, $X_{11}$, $X_{12}$, $X_{13}$, $X_{14}$, $X_{15}$, $X_{16}$, $X_{17}$, $X_{18}$, $X_{19}$, $X_{20}$, $X_{21}$, $X_{22}$ or $X_{23}$ is conservatively substituted with another D-enantiomeric residue.

2. (Canceled).

3. (Previously Presented) The ApoA-I agonist compound of Claim 1 which is the altered D-enantiomeric peptide or peptide analogue according to formula (I).

4. (Previously Presented) The ApoA-I agonist compound of Claim 3 in which the D-enantiomeric hydrophobic residues are fixed according to formula (I) and at least one non-fixed residue is conservatively substituted with another D-enantiomeric residue.

5. (Previously Presented) The ApoA-I agonist compound of Claim 4 in which:

$X_1$ is D-Pro (p), Gly (G) or D-Ala (a);

$X_2$ is D-Ala (a), D-Leu (l) or D-Val (v);

$X_3$ is D-Leu (l) or D-Phe (f);

$X_5$ is D-Leu (l) or D-Phe (f);

$X_6$ is D-Leu (l) or D-Phe (f);

$X_9$ is D-Leu (l) or Gly (G);

$X_{10}$ is D-Leu (l), D-Trp (w) or Gly (G);

$X_{13}$ is D-Leu (l), Gly (G) or D-Aib;

$X_{14}$ is D-Leu (l), D-Nal, D-Trp (w) or Gly (G);

$X_{16}$ is D-Ala (a), D-Nal, D-Trp (w), Gly (G), D-Leu (l) or D-Phe (f);

$X_{17}$ is D-Leu (l), Gly (G) or D-Nal;

$X_{21}$ is D-Leu (l); and

at least one of $X_4$, $X_7$, $X_8$, $X_{11}$, $X_{12}$, $X_{15}$, $X_{18}$, $X_{19}$, $X_{20}$, $X_{22}$ and $X_{23}$ is conservatively substituted with another D-enantiomeric residue.

6. (Previously Presented) The ApoA-I agonist compound of Claim 5 in which the D-enantiomeric hydrophilic residues are fixed according to formula (I) and at least one non-fixed residue is conservatively substituted with another D-enantiomeric residue.

7. (Previously Presented) The ApoA-I agonist compound of Claim 6 in which:

$X_4$ is D-Asp (d) or D- Glu (e);

$X_7$ is D-Lys (k), D-Arg (r) or D-Orn;

$X_8$ is D-Asp (d) or D-Glu (e);

$X_{11}$ is D-Asn (n) or D-Gln (q);

$X_{12}$ is D-Glu (e) or D-Asp (d);

$X_{15}$ is D-Asp (d) or D-Glu (e);

$X_{18}$ is D-Gln (q), D-Asn (n), D-Lys (k) or D-Orn;

$X_{19}$ is D-Gln (q), D-Asn (n), D-Lys (k) or D-Orn;

$X_{20}$ is D-Lys (k) or D-Orn;

$X_{22}$ is D-Lys (k) or D-Orn;

$X_{23}$ is absent or D-Lys (k); and

at least one of $X_1$, $X_2$, $X_3$, $X_5$, $X_6$, $X_9$, $X_{10}$, $X_{13}$, $X_{14}$, $X_{16}$, $X_{17}$ and $X_{21}$ is conservatively substituted with another D-enantiomeric residue.

8. (Previously Presented) The ApoA-I agonist compound of Claim 7 in which $X_3$ is D-Leu (l) or D-Phe (f), $X_6$ is D-Phe (f), $X_9$ is D-Leu (l) or Gly (G), $X_{10}$ is D-Leu (l) or D-Trp (w) or Gly (G) and at least one of $X_1$, $X_2$, $X_5$, $X_{13}$, $X_{14}$, $X_{16}$, $X_{17}$ and $X_{21}$ is conservatively substituted with another D-enantiomeric residue.

9. (canceled)

13. (Previously Presented) The ApoA-I agonist compound of Claim 12 in which:

the "-" between residues designates -C(O)NH-;

$Z_1$ is $H_2N$-; and

$Z_2$ is -C(O)OH or a salt thereof.

14. (Previously Presented) The ApoA-I agonist compound of Claim 13, in which:

$X_1$ is D-Ala (a), Gly (G), D-Asn (n), D-Gln (q), D-Asp (d) or D-Pro (p);

$X_2$ is D-Ala (a), D-Val (v) or D-Leu (l);

$X_3$ is D-Leu (l) or D-Phe (f);

$X_4$ is D-Asp (d) or D-Glu (e);

$X_5$ is D-Leu (l) or D-Phe (f);

$X_6$ is D-Leu (l) or D-Phe (f);

$X_7$ is D-Lys (k), D-Arg (r) or D-Orn;

$X_8$ is D-Asp (d) or D-Glu (e);

$X_9$ is D-Leu (l) or Gly (G);

$X_{10}$ is D-Leu (l), D-Trp (w) or Gly (G);

$X_{11}$ is D-Asn (n) or D-Gln (q);

$X_{12}$ is D-Glu (e) or E-Asp (d);

$X_{13}$ is Gly (G), D-Leu (l) or D-Aib;

$X_{14}$ is D-Leu (l), D-Nal, D-Trp (w) or Gly (G);

$X_{15}$ is D-Asp (d) or D-Glu (e);

$X_{16}$ is D-Ala (a), D-Nal, D-Trp (w), D-Leu (l), D-Phe (f) or Gly (G);

$X_{17}$ is Gly (G), D-Leu (l) or D-Nal;

$X_{18}$ is D-Gln (q), D-Asn (n), D-Lys (k) or D-Orn;

$X_{19}$ is D-Gln (q), D-Asn (n), D-Lys (k) or D-Orn;

$X_{20}$ is D-Lys (k) or D-Orn;

$X_{21}$ is D-Leu (l);

$X_{22}$ is D-Lys (k) or D-Orn; and

$X_{23}$ is absent or D-Lys (k).

15. (Previously Presented) The ApoA-I agonist compound of Claim 14, in which $X_{23}$ is absent.

16. (Previously Presented) The ApoA-I agonist compound of Claim 13 or 14, in which one of $X_{18}$ or $X_{19}$ is D-Gln (q) or D-Asn (n) and the other of $X_{18}$ or $X_{19}$ is D-Lys (k) or D-Orn.

17. (Previously Presented) The ApoA-I agonist compound of Claim 14 in which each of $X_9$, $X_{10}$, $X_{13}$, $X_{14}$, $X_{15}$ and $X_{17}$ is other than Gly (G).

18.-28. (Canceled).

29. (Previously Presented) An ApoA-I agonist-lipid complex comprising an ApoA-I agonist compound and a lipid, wherein the ApoA-I agonist compound is a peptide or peptide analogue according to Claim 1.

30.-33. (Canceled).

34. (Previously Presented) The ApoA-I agonist-lipid complex of Claim 29 in which the lipid is sphingomyelin.

35. (Currently Amended) The ApoA-I agonist-lipid complex of Claim 34 ~~which is~~ in which the ApoA-I agonist-lipid complex is in the form of a lyophilized powder

36. (Canceled).

37. (Previously Presented) A pharmaceutical composition comprising an ApoA-I agonist compound and a pharmaceutically acceptable carrier, excipient or diluent, wherein the ApoA-I agonist compound is a peptide or peptide analogue according to Claim 1.

38.- 41. (Canceled).

42. (currently amended) ~~The~~ A pharmaceutical composition comprising a pharmaceutically acceptable carrier, excipient or diluent and an ApoA-1 agonist-lipid complex wherein the ApoA-I agonist is a peptide or peptide analog of Claim 1. ~~of Claim 37, in which the ApoA-I agonist is in the form of an ApoA-I agonist-lipid complex, said complex comprising the ApoA-I agonist compound and a lipid.~~

43-56. (Canceled).

57. (Previously Presented) An ApoA-I agonist compound which is a D-enantiomeric peptide of SEQ ID NO.:4.